Real-world experience of second-line axitinib in metastatic renal cell carcinoma: analysis of the Swedish population.
Future Oncol
; 20(20): 1385-1392, 2024.
Article
em En
| MEDLINE
| ID: mdl-39057291
ABSTRACT
Aim:
Assess the time-to-treatment discontinuation (TTD) and overall survival (OS) in a Swedish metastatic renal cell carcinoma (mRCC) nationwide cohort who received second-line axitinib.Methods:
Retrospective analysis of 110 patients with mRCC treated with second-line axitinib in Sweden (2012-2019). Patients included in the study received axitinib after mainly first-line sunitinib or pazopanib.Results:
The median (95% CI) TTD of patients who received second-line axitinib was 5.2 (3.7-6.1) months with 6 (5.5%) patients still receiving treatment at the time of analysis. Median (95% CI) OS was 12.2 (7.7-14.2) months.Conclusion:
The results are consistent with previous findings in mRCC and add to the evidence demonstrating efficacy of second-line axitinib, after failure of a prior anti-angiogenic therapy in a real-world setting.Clinical Trial Registration NCT04669366 (ClinicalTrials.gov).
[Box see text].
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Carcinoma de Células Renais
/
Inibidores de Proteínas Quinases
/
Axitinibe
/
Neoplasias Renais
Limite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
País/Região como assunto:
Europa
Idioma:
En
Revista:
Future Oncol
Ano de publicação:
2024
Tipo de documento:
Article